Global Health Update: Mpox Vaccines, Biotech IPOs, and More

This summary covers recent health news, including Congo's delivery of mpox vaccines, BioAge's IPO filing, a Supreme Court decision on family planning funding in Oklahoma, and Eli Lilly's agreements in Africa. Other topics include Johnson & Johnson's talc settlement, EU diabetes drug shortages, Rite Aid's restructuring, Amgen's obesity drug trials, UK diabetes drug findings, and increased production of ADHD medication in the US.

A summary of the latest developments in health news includes the Democratic Republic of Congo's receipt of its first mpox vaccine doses this Thursday amid a U.N.-declared global health emergency. Authorities face hurdles stemming from a vaccine shortage, complicating containment efforts.

Meanwhile, in the United States, obesity-therapy biotech startup BioAge Labs has filed for an initial public offering (IPO) to capitalize on investor enthusiasm. Also, the U.S. Supreme Court endorsed the Biden administration's decision to slash $4.5 million in family planning grants for Oklahoma due to abortion referral disputes.

In related news, Eli Lilly has entered a deal with Egypt's Eva Pharma to produce its arthritis drug Olumiant in Africa. Johnson & Johnson plans an additional $1.1 billion for talc settlement payments. Novo Nordisk reports that despite intermittent shortages of its diabetes drug Ozempic in the EU, not all member states will be affected. Lastly, the DEA has permitted increased production of Takeda's ADHD medication Vyvanse to alleviate U.S. shortages.

(With inputs from agencies.)